StockNews.com started coverage on shares of Titan Pharmaceuticals (NASDAQ:TTNP – Free Report) in a research note issued to investors on Wednesday morning. The brokerage issued a sell rating on the specialty pharmaceutical company’s stock.
Titan Pharmaceuticals Stock Up 9.8 %
Shares of TTNP stock opened at $3.57 on Wednesday. Titan Pharmaceuticals has a fifty-two week low of $3.03 and a fifty-two week high of $14.80. The firm’s 50 day moving average price is $3.46 and its two-hundred day moving average price is $4.58.
Titan Pharmaceuticals (NASDAQ:TTNP – Get Free Report) last announced its quarterly earnings results on Friday, January 3rd. The specialty pharmaceutical company reported ($0.83) earnings per share (EPS) for the quarter.
About Titan Pharmaceuticals
Titan Pharmaceuticals, Inc, a pharmaceutical company, develops therapeutics for the treatment of chronic diseases in the United States and internationally. It develops products based on ProNeura, a proprietary long-term drug delivery platform. It also develops TP-2021 in combination with ProNeura technology for the treatment of chronic pruritus, a severe and debilitating condition defined as itching of the skin lasting longer than six weeks; and Nalmefene implant program for the prevention of opioid relapse following detoxification of patients suffering opioid use disorder.
Recommended Stories
- Five stocks we like better than Titan Pharmaceuticals
- What to Know About Investing in Penny Stocks
- 3 Must-Have ETFs Set to Dominate This Quarter
- What Does Downgrade Mean in Investing?
- Seeking Stability? These 3 Stocks Offer Strong Potential
- What is a Death Cross in Stocks?
- Trade War Bargain Stocks: Top 3 Picks Too Good to Pass Up
Receive News & Ratings for Titan Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Titan Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
